country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-150730

Copy Link Print Information

FAK-IN-6

FAK-IN-6 is a potent FAK inhibitor with an IC₅₀ value of 1.415 nM. FAK-IN-6 has anti-proliferative activity against certain cancer cell lines. FAK-IN-6 can be used for researching pancreatic cancer.

For research use only. We do not sell to patients.

CAS No.: 3033299-38-3
Formula: C₂₅H₃₁ClN₅O₆PS
Molecular Weight:596.04

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (267 KB)

FAK-IN-6 Chemical Structure

CAS No.: 3033299-38-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

IC₅₀: 1.415 nM (FAK)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
ASPC1	IC₅₀	0.1596 μM Compound: 9h	Antiproliferative activity against human ASPC1 cells harboring KRAS,TP53,CDKN2A and DPC4/SMAD4 mutations assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human ASPC1 cells harboring KRAS,TP53,CDKN2A and DPC4/SMAD4 mutations assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 35872546]
KM3/BTZ	IC₅₀	2.286 μM Compound: 9h	Antiproliferative activity against bortezomib- resistant human KM3/BTZ cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against bortezomib- resistant human KM3/BTZ cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 35872546]
L02	IC₅₀	1.398 μM Compound: 9h	Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 35872546]
MIA PaCa-2	IC₅₀	0.7679 μM Compound: 9h	Antiproliferative activity against human MIA PaCa-2 cells harboring KRAS,TP53,CDKN2A and DPC4/SMAD4 mutations assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MIA PaCa-2 cells harboring KRAS,TP53,CDKN2A and DPC4/SMAD4 mutations assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 35872546]
NCI-H1975	IC₅₀	1.355 μM Compound: 9h	Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 35872546]
Raji	IC₅₀	1.13 μM Compound: 9h	Antiproliferative activity against human Raji cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human Raji cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 35872546]

In Vitro

FAK-IN-6 (compound 9h) (0-10 μM; 72 h) has anti-proliferative activity against pancreatic cancer cells, lung cancer cells and lymphoma cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

AsPC-1, PaCa-2, H1975, KM3/BTZ, Raji and L-02^[1]
Concentration:

0-10 μM
Incubation Time:

72 h
Result:

Exhibited anti-proliferative activity against AsPC-1, PaCa-2, H1975, KM3/BTZ, Raji and L-02 with IC₅₀s of 0.9886 ± 0.0086 μM, 5.274 ± 0.9312 μM, 2.918 ± 0.0821 μM, 2.315 ± 0.2969 μM, 1.320 ± 0.2973 μM and 1.220 ± 0.2683 μM.

Chemical Information

CAS No. 3033299-38-3
Molecular Weight 596.04
Formula C₂₅H₃₁ClN₅O₆PS
SMILES

O=C(NC1=CC=C(NC2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(C(C)C)=O)=N2)C=C1)CP(OCC)(OCC)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (267 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zheng X, et al. Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FAK inhibitors for the potential treatment of pancreatic cancer. Eur J Med Chem. 2022 Jul 19;241:114607. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote